Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Kiniksa Pharmaceuticals (KNSA) stock.

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Date	Firm	Analyst	Action	Rating Change	Price Target
—	JP Morgan	Anupam Rama	PT Raise	Overweight	$107→$122
—	Goldman Sachs	Paul Choi	PT Raise	Buy	$90→$101
—	Wedbush	David Nierengarten	PT Raise	Outperform	$99→$102
—	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$87→$110
—	Goldman Sachs	Paul Choi	PT Raise	Buy	$75→$90
—	JP Morgan	Anupam Rama	PT Raise	Overweight	$72→$107
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$64→$98
—	Wedbush	David Nierengarten	PT Raise	Outperform	$72→$99
—	Citigroup	Geoff Meacham	PT Raise	Buy	$60→$100
—	Goldman Sachs	Paul Choi	PT Raise	Buy	$60→$75
—	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$57→$74
—	Wedbush	David Nierengarten	PT Raise	Outperform	$59→$72
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$62→$64
—	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$60
—	Wedbush	David Nierengarten	PT Raise	Outperform	$58→$59
—	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$53→$57
—	Jefferies	Roger Song	PT Raise	Buy	$58→$71
—	Wedbush	David Nierengarten	PT Raise	Outperform	$53→$58
—	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$50→$53
—	Wedbush	David Nierengarten	PT Raise	Outperform	$50→$53

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.

Benzinga Newsdesk

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

People Also Watch

People Also Watch

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Kiniksa Pharmaceuticals (KNSA) Stock Price Target 2026

Latest Upgrades and Downgrades for Kiniksa Pharmaceuticals Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PROWedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PROWells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

People Also Watch

People Also Watch

Analyst Ratings News

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PROWedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PROWells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PROGoldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PROJP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

PRO
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107